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Cytotoxic necrotizing factor type 1 (CNF1) is a 115-kDa toxin that activates Rho GTPases and is produced
by uropathogenic Escherichia coli (UPEC). While both epidemiological studies that link CNF1 production by
E. coli with urinary tract disease and the cytopathic effects of CNF1 on cultured urinary tract cells are
suggestive of a role for the toxin as a UPEC virulence factor, few in vivo studies to test this possibility have been
reported. Therefore, in this investigation, we evaluated the importance of CNF1 in a murine model of urinary
tract infection (UTI) by comparing the degree of colonization and damage induced by three different CNF1-
producing E. coli strains with isogenic CNF1-deficient derivatives. The data from single-strain challenge
experiments with C3H/HeOuJ mice indicated a trend toward higher counts of the wild-type strains in the urine
and bladders of these animals up to 3 days after challenge in two of three strain pairs. Furthermore, this
difference was statistically significant at day 2 of infection with one strain pair, C189 and C189cnf1. To control
for the animal-to-animal variability inherent in this model, we infected C3H/HeOuJ mice with a mixture of
CNF1-positive and -negative isogenic derivatives of CP9. The CNF1-positive strain was recovered in higher
numbers than the CNF1-negative strain in the urine, bladders, and kidneys of the mice up to 9 days
postinfection. These striking coinfection findings, taken with the trends observed in single-strain infections, led
us to conclude that CNF1-negative strains were generally attenuated compared to the wild type in the
C3H/HeOuJ mouse model of UTI. Furthermore, histopathological examination of bladder specimens from
mice infected with CNF1-positive strains consistently showed deeper, more extensive inflammation than in
those infected with the isogenic mutants. Lastly, we found that CNF1-positive strain CP9 was better able to
resist killing by fresh human neutrophils than were CP9cnf1 bacteria. From these data in aggregate, we propose
that CNF1 production increases the capacity of UPEC strains to resist killing by neutrophils, which in turn
permits these bacteria to gain access to deeper tissue and persist better in the lower urinary tract.
Acute infections of the bladder and kidneys in otherwise
healthy individuals are among the most common types of bac-
terial infections in humans (20, 44). Indeed, there are an esti-
mated 7 million episodes of acute cystitis and 250,000 cases of
pyelonephritis in the United States every year (21, 39). This
high incidence of disease disproportionately affects women,
about 40% of whom experience cystitis in their lifetimes.
Treatment of cystitis in women has been estimated to cost one
billion dollars annually (44).
Escherichia coli is the most frequently isolated bacterial
cause of uncomplicated urinary tract infection (UTI). Uro-
pathogenic E. coli (UPEC) produces a number of virulence-
associated factors that include P fimbriae, hemolysin, aerobac-
tin, and cytotoxic necrotizing factor type 1 (CNF1) (29). CNF1
is a chromosomally encoded UPEC toxin that catalyzes the
deamidation of the small GTPases RhoA, Rac, and Cdc42 (12,
14, 30, 42). Deamidation by CNF1 renders these GTPases
constitutively active, which in most cells leads to the formation
of actin stress fibers, lamellipodia, and filopodia. HEp-2 cells,
which have been used as the prototypic cells for evaluation of
CNF1 toxicity, not only display actin stress fibers but also
become multinucleated (6, 10, 40). Additionally, CNF1 has
been reported to (i) induce phagocytosis in epithelial cells (9,
11), (ii) reduce CR3-dependent phagocytosis in monocytes (5),
(iii) increase the permeability of Caco-2 intestinal cell mono-
layers (14), (iv) efface the brush border of and decrease the
transmigration of polymorphonuclear leukocytes (PMN)
across a T84 monolayer (18), (v) inhibit wound repair in T24
bladder cells and Hs 738 fibroblast cells (24), and (vi) kill 5637
bladder cells through an apoptotic mechanism (34). Thus,
CNF1 affects a variety of cellular functions in vitro, presumably
through activation of the Rho GTPases. However, the role of
this toxin in the pathogenesis of UTI remains to be delineated.
Several groups have reported an epidemiological link be-
tween the presence of the cnf1
1 genotype or the production of
CNF1 and E. coli strains that cause extraintestinal disease.
Indeed, Yamamoto et al. showed that 61% of UTI isolates and
38% of bacteremia isolates harbored the cnf1
1 gene, as op-
posed to only 10% of commensal fecal isolates (45). Further-
more, Mitsumori et al. reported that 64% of prostatitis isolates
and 36% of pyelonephritis isolates were cnf1
1 (35) and Andreu
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and colleagues reported that the percentages of cnf11 prostati-
tis, pyelonephritis, and cystitis isolates were 63, 48, and 44%,
respectively (3). Caprioli et al. found that 40% of UTI isolates
tested positive for CNF1 expression, while only 0.9% of fecal
isolates produced CNF1 (6). The common finding of cnf1
1 in
E. coli strains that cause extraintestinal infections is also con-
sistent with the strong correlation between the presence of
cnf1
1 and the gene for hemolysin, hly, in these isolates. In fact,
Yamamoto et al. reported that approximately 76% of isolates
of E. coli from extraintestinal sites that were hly1 were also
cnf1
1, while 98% of cnf1
1 strains were also hly1 (45).
In this study, we used a mouse model of ascending UTI to
evaluate the role that CNF1 may play in the pathogenesis of
UTI. We found that in two of three CNF1-positive UPEC
strains tested, the bacterial counts in the bladders and urine of
mice early in infection were higher than in those of animals
inoculated with the respective isogenic cnf1 deletion mutant. In
a few single-strain studies and in all mixed-inoculum studies,
this difference was statistically significant. We also showed that
CNF1 may alter the host response to infection, therefore al-
lowing the bacteria to penetrate deeper into the muscular wall
of the bladder and cause more severe and prolonged infection.
MATERIALS AND METHODS
Bacterial strains, plasmids, media, and growth conditions. The bacterial
strains and plasmids used in this study are listed in Table 1. The media used were
Luria Bertani (LB) broth, LB agar, and MacConkey agar (Difco, Becton-Dick-
inson, Sparks, Md.). When appropriate, ampicillin was used at 100 mg/ml of
medium. Chloramphenicol was used at 30 mg/ml where necessary. Bacteria were
routinely grown at 37°C.
Cloning of cnf11. Commercially synthesized primers (Life Technologies, Inc.,
Gaithersburg, Md.) were designed to amplify cnf11 from E. coli strain J96 (23)
by PCR. The sequences of the primers were as follows: forward, 59-TATTAA
TCTTCACAGAGGAG-39; reverse, 59-GGCCAATAAATAATTTCCCGAAT
C-39 (8). Amplification reaction mixtures contained 13 PCR buffer (Perkin-
Elmer, Foster City, Calif.), 0.2 mM each deoxynucleoside triphosphate (Perkin-
Elmer), 1.0 mM each primer, 1.5 mM MgCl2, 10 to 20 ng of template DNA, and
2.5 U of Taq polymerase (Perkin-Elmer). Reaction mixtures were incubated in a
thermocycler for 30 consecutive cycles of 1 min at 95°C, 1 min at 50°C, and 3 min
at 72°C with a final extension at 72°C for 10 min. The PCR amplification product
was purified (Wizard DNA Purification Kit; Promega Corp., Madison, Wis.)
from low-melting-point agarose (SeaPlaque; BioWhittaker Molecular Applica-
tions, Rockland, Maine) and cloned in the SmaI site of pBluescript II SK(2)
(Stratagene Cloning Systems, La Jolla, Calif.). The cnf11 plasmid clone pHLK102
(Table 1) expressed CNF1 biological activity in the HEp-2 multinucleation assay
and contained the restriction enzyme recognition sites predicted from the pub-
lished cnf11 DNA sequence (8).
A 4.4-kb cnf11 EcoRI-StuI fragment from the cosmid 2CO2 (obtained from D.
Berg [13, 43]) was cloned into pBC KS(2) (Stratagene Cloning Systems) to
generate pHLK116. The cnf11 fragment was reisolated following digestion of
pHLK116 with SacI and SalI and subcloned into pSX34lacZa (obtained from
S.-Y. Xu, New England Biolabs, Beverly, Mass.) to produce pHLK140 (Table 1).
Construction of cnf1 isogenic mutants. An in-frame deletion mutation
(pHLK120) was constructed by the removal of an internal 1.2-kb BclI cnf11
fragment from pHLK102. The mutation (Dcnf-120) produced a truncated CNF1
protein that was detectable with CNF1-specific polyclonal antiserum (34), but
strains carrying the Dcnf-120 mutation expressed no detectable CNF1 biological
activity. A 2.0-kb BssHII fragment from pHLK120 that contained the Dcnf-120
mutation was ligated into the BssHII site in the suicide vector pAM450 (31) to
yield pHLK125, which was subsequently used as previously described (16, 31) to
introduce the Dcnf-120 mutation into different UPEC strains. For allelic ex-
change, bacteria were transformed with pHLK125 under selection for ampicillin
resistance (Ampr) at 30°C. Transformants then underwent selection for Ampr at
42°C to isolate cointegrates that were subsequently plated at 30°C on LB agar
without added NaCl and containing 5% sucrose to allow resolution of the
plasmid. The resulting isogenic mutants were screened for loss of plasmid mark-
ers and loss of CNF1 activity. The replacement of the wild-type cnf1 gene with
the Dcnf-120 allele was confirmed by PCR, Southern blot, and Western blot
analyses. E. coli strains that carried the Dcnf-120 mutation were complemented
in vitro with the wild-type cnf1 gene in pHLK102 or pHLK140 (Table 1). Growth
curves of the wild-type and mutant strains were done in minimal-salts liquid
containing glucose and in L broth over a 24-h period. The growth rates of the
strain pairs appeared indistinguishable. Moreover, the plating efficiencies of the
mutants on L agar and MacConkey agar were indistinguishable from those of the
parental strains. All strains were tested for retention of the O antigen, capsular
antigen (where present), type 1 pili, P fimbriae, hemolysin, and lipopolysaccha-
ride by standard procedures.
TABLE 1. Bacterial strains and plasmids used in this study
Strain (serotype if
relevant) or plasmid Relevant genotype or phenotype Reference or source
E. coli strains
DH5a F2 f80 dlacZDM15 D(lacZYA-argF)U169 endA1 recA1 hsdR17(rK
2mK
1)
deoR thi-1 phoA supE44 l2 gyrA96 relA1
Life Technologies, Inc.,
Gaithersburg, Md.
J96 (O4:H5:K6) hly1 cnf1
1 Pyelonephritis; 23
CP9 (O4:H5:K54) hly1cnf1
1 Blood; 41
C85 (O2:H2) hly1 cnf1
1 Cystitis; 45
C189 (O2:H2) cnf1
1 Cystitis; 45
J96cnf1 hly
1 cnf1 This study
CP9cnf1 hly
1 cnf1 This study
C85cnf1 hly
1 cnf1 This study
C189cnf1 cnf1 This study
CP9lacZ hly1 cnf1
1 lacZ This study
Plasmids
pBluescript II SK(2) Ampr Stratagene, La Jolla, Calif.
pHLK102 cnf1
1 from J96 cloned in pBluescript II SK(2), Ampr This study
pHLK116 4.4-kb cnf1
1 EcoRI-StuI fragment from 2CO2 cloned in pBC KS(2)
pHLK120 pHLK102 with internal BclI fragment of cnf1
1 deleted; cnf1 Amp
r This study
pHLK125 2.0-kb BssHII fragment from pHLK120 cloned in pAM450; cnf1
2CO2 cnf1
1 cosmid clone derived from J96 13, 43
pSX34lacZa Chlr; derived from pSC101 S.-Y. Xu, New England
Biolabs, Inc.
pHLK140 cnf1
1 from 2CO2 cloned in pSX34lacZa; Chlr This study
pAM450 Derived from pMAK705; sacB/R Ampr 31
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Isolation of CP9lacZ. Standard methods (32) were used to isolate and char-
acterize a Lac2 derivative of E. coli strain CP9, designated CP9lacZ (Table 1).
Phenotypic and complementation analyses of CP9lacZ localized the mutation to
lacZ, and the mutant was otherwise indistinguishable from strain CP9 in vitro or
in vivo.
HEp-2 multinucleation assays. Ninety-six-well tissue culture plates were
seeded with 4 3 103 HEp-2 cells per well and incubated for 4 h at 37°C with 5%
CO2. Overnight bacterial cultures were harvested by centrifugation, concen-
trated by resuspension in phosphate-buffered saline plus gentamicin (100 mg/ml),
and disrupted by sonication. The resultant lysates were clarified by centrifugation
at 4°C and sterilized by filtration. Serial dilutions of the lysates were applied to
the HEp-2-seeded wells, and the microtiter plates were further incubated for
72 h before the wells were fixed and stained with Leukostat (Fisher Scientific,
Pittsburgh, Pa.). Multinucleation of HEp-2 cells was assessed by microscopy.
Mouse UTI model. Animal experiments were carried out in accordance with
the principles outlined in the Guide for the Care and Use of Laboratory Animals
(38). The mouse ascending UTI model was performed as previously described
(15, 28, 36, 37). All of the E. coli strains evaluated in this model were first passed
through mice as described below to ensure that the strains were not attenuated
as a result of routine laboratory culture. The bacteria were isolated from infected
kidneys at 2 to 5 days postinfection and stored at 270°C. The strains did not lose
any virulence factors or CNF1 expression due to animal passage. To prepare
inocula for mice, mouse-passaged bacteria were harvested from an LB agar plate
after overnight incubation and resuspended in sterile, nonpyrogenic saline to an
A600 of 1.12. Six milliliters of the bacterial suspension was pelleted and resus-
pended in 0.5 ml of saline to give a bacterial density of 109 CFU/ml. This
suspension was adjusted by dilution so that 1 3 107 to 1 3 108 CFU were
contained in 10 or 25 ml. The inoculum was pipetted into an adapter tube (6-in.
Male/Female line; Surgimedics, The Woodlands, Tex.) connected to a 30-gauge,
0.5-in. sterile needle. The pipette tip was left in the tubing, and an electronic
EDP pipettor (Rainin Instrument Co., Woburn, Mass.) was attached to the tip.
Four- to six-week-old C3H/HeOuJ and BALB/c female mice were obtained
from Jackson Laboratory (Bar Harbor, Maine). C3H/HeOuJ mice were chosen
for these experiments because they are easily infected by UPEC strains, and
while they are congenic to C3H/HeJ mice, they do not express the lipopolysac-
charide-hyporesponsive defect found in the latter strain. Mice were anesthetized
with methoxyflurane (Metofane; Schering-Plough Animal Health Corp., Union,
N.J.) or isoflurane (Forane; Anaquest, Madison, Wis.) and catheterized with a
sterile 1-in. piece of tubing (inside diameter, 0.28 mm; outside diameter, 0.61
mm; Intramedic; Becton-Dickinson). Urine expressed from the bladder was
collected on a sterile swab and streaked onto an LB plate to check for pre-
existing bacteriuria. The needle connected to the inoculating apparatus was
inserted into the catheter, and the Rainin EDP was used to deliver 10 or 25 ml
over a 30-s period into the bladder of the anesthetized animal. After the inoc-
ulum was instilled, the catheter was removed from the mouse and the mouse was
placed in a cage to recover from the anesthesia. Mice were given food and water
ad libitum and were monitored over a period of 1 to 9 days for any signs of
distress.
Mice were euthanatized with an overdose of methoxyflurane or isoflurane, and
urine, bladders, and kidneys were collected aseptically. Urine was serially diluted
in saline and plated on LB agar. Each organ was bisected; one half was homog-
enized for bacterial counts, and the other half was used to prepare histology
sections. Tissue homogenates were diluted and plated on LB agar to quantitate
bacterial CFU. In some cases, the remainder of the homogenate was inoculated
into LB broth to recover bacteria present at numbers below the limit of detection
by direct plating (approximately 10 CFU per specimen). Isolates from positive
broth cultures were tested to confirm their identity. Specimens that were negative
upon direct plating but which yielded positive broth cultures were assumed to
contain 1 CFU. Isolates recovered from the mice were tested in the HEp-2
multinucleation assay for expression of functional CNF1 and were found in all
cases to retain the phenotype of the strain that was inoculated.
Histopathology. Organs were soaked in 10% phosphate-buffered formalin for
a minimum of 4 h, embedded in paraffin, and cut into 5-mm sections. The slides
were stained with hematoxylin and eosin and examined for depth of inflamma-
tion. Bladder sections were also stained with Brown-Brenn stain for bacteria.
Sections were coded and viewed in a blinded fashion under 3600 magnification,
and the area of greatest inflammation was located. Neutrophils and band forms
were counted in that area. Severity of inflammation was scored according to the
following scale: 0 to 25 neutrophils present, mild inflammation; 26 to 50 neutro-
phils present, moderate inflammation; greater than 50 neutrophils present, se-
vere inflammation. No neutrophils were observed in saline-inoculated control
animal sections.
Neutrophil killing of bacteria in vitro. Overnight cultures of bacteria were
washed and suspended in Hanks’ balanced salt solution containing gelatin (1.0
mg/ml). Fresh human neutrophils were isolated from whole venous blood and
suspended in Hanks’ balanced salt solution–1.0 mg of gelatin per ml (4). Bacteria
and neutrophils were mixed at ratios of two to five bacteria per neutrophil and
incubated at 37°C with gentle tumbling. After 15 and 45 min of incubation,
samples were plated on LB agar. The percentage of viable bacteria after incu-
bation with neutrophils was calculated according to the following formula: %
viable bacteria 5 (number of bacterial CFU in the mixtures at 15 or 45 min/
number of bacterial CFU added to the mixtures at the start of the assay) 3 100.
Statistical analysis. The geometric mean number of CFU of bacteria from the
urine, bladders, or kidneys of a group of mice infected with the wild-type strain
was compared to the geometric mean number of CFU in mice infected with the
mutant strain by using unpaired Student t tests. When the geometric mean
numbers of CFU of a group of strains were compared, as in Fig. 1, an analysis of
variance was used to evaluate the variance, followed by unpaired Student t tests
to compare the means of two strains. The numbers of CFU from mice coinfected
with two strains were compared by Student t tests of paired log10 numbers. A
Student t test of paired samples was also used to examine the data obtained from
the neutrophil-killing experiments.
RESULTS
Rationale for selection of E. coli strains for mouse UTI
studies. Experiments were initially undertaken in the mouse
UTI model with the well-characterized O4:H5:K6 UPEC
strain J96. However, we concluded, on the basis of a set of
experiments in which we varied a number of parameters to
optimize the model, that the colonization levels of J96 were
invariably too low to allow us to discern a difference between
the wild-type and mutant J96cnf1 strains. Therefore, we sought
to find CNF1-expressing UPEC strains that were more virulent
(i.e., colonized the bladder and/or kidneys at higher levels)
than J96 in the mouse model. For that purpose, we compared
J96 with three independent CNF1-producing clinical isolates,
CP9, C85, and C189 (Table 1) (41, 45). Colonization levels in
the urine, bladder, and kidneys were significantly higher than
those of J96 for all three strains (P , 0.05) except for C189 in
the bladder (Fig. 1). Therefore, we proceeded to prepare iso-
genic cnf1 mutants of these strains (designated CP9cnf1,
C85cnf1, and C189cnf1) by allelic exchange as we had done for
J96. We then selected one strain pair, CP9 and CP9cnf1, to use
in a series of studies in the mouse UTI model to assess the
impact on relative bacterial counts of the time when samples
were harvested after infection (kinetics of infection), the strain
of mouse used as the host animal, and the challenge dose.
When we evaluated the importance of these variables in the
pairwise comparison, we also, on occasion, tested other CNF1-
positive and CNF1-negative pairs.
Kinetics of infection of C3H/HeOuJ mice with CP9 and
CP9cnf1 in the UTI model. The goal of our first set of exper-
iments with CP9 and CP9cnf1 was to define the optimal time
for harvesting of infected urine, bladders, and kidneys for
comparative enumeration. For this purpose, 30 mice per strain
were inoculated with 1.9 3 107 CFU and 10 mice per strain
were euthanatized at 1, 3, and 5 days postchallenge. At day 1
after inoculation, urine and bladder samples collected from
mice infected with CP9 contained higher numbers of bacteria
than did samples collected from CP9cnf1-infected mice (Fig.
2A). However, at day 3 postinfection, bacterial counts in the
urine, bladders, and kidneys of mice infected with either strain
were equivalent, although the absolute numbers for each type
of sample were higher for both strains than on day 1 of infec-
tion (Fig. 2B). By 5 days after infection, mice challenged with
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CP9 again had somewhat higher bacterial numbers in their
urine than did mice given CP9cnf1 but the bacterial numbers in
the bladder slightly favored the mutant while equal numbers of
bacteria of both strains were present in the kidney samples
(Fig. 2C). Although none of the observed differences were
statistically significant, the trend toward higher numbers of
CNF1-positive bacteria in the urine and bladder on the first
day following inoculation led us to focus on colonization in the
first days of infection.
Comparison of CP9 and CP9cnf1 early in infection of C3H/
HeOuJ or BALB/c mice in the UTI model and influence of
challenge dose on infection of C3H/HeOuJ mice. For the next
series of kinetic studies, we again compared our prototypic
strains, CP9 and CP9cnf1, but focused only on days 1 to 3 of
infection. We also compared the influence of the mouse strain
on the outcome at day 1 postchallenge. As with the previous
kinetic experiments, 1 day after infection, C3H/HeOuJ mice
challenged with strain CP9 had higher bacterial numbers in
their urine and bladders than did mice challenged with the
mutant (Fig. 3A). When identical experiments were done with
BALB/c mice (Fig. 3B), the bladder samples had slightly
higher numbers of wild-type CP9 bacteria while slightly higher
numbers of CNF1-negative bacteria were present in the urine
and kidney samples. Two days after infection, urine samples of
C3H/HeOuJ mice infected with CP9 contained slightly more
bacteria than did samples from CP9cnf1-infected mice (Fig.
3C). Bladders and kidneys were infected equally with the wild-
type and mutant strains. BALB/c mice were not tested at this
time point. From these data, we concluded that day 1 after
challenge of C3H/HeOuJ permitted the best discrimination
between the CNF1-postive CP9 strain and its isogenic mutant
and that BALB/c mice did not display this difference across all
sample types. Therefore, we elected to use C3H/HeOuJ mice
in the remaining studies.
We also tested the effects of inoculum size in the early
kinetic studies. In all previous studies, we used '2 3 107
bacteria as our challenge inoculum. In these experiments, we
asked whether, if we raised the dose of the inoculum, we could
discern a difference between the counts of CP9 and its isogenic
mutant later in infection than day 1. We found that when we
elevated the challenge inoculum to 108 bacteria, the answer
was yes, at least for the urine and bladder samples (Fig. 3D).
Thus, in this higher challenge dose experiment, significantly
more CP9 than CP9cnf1 bacteria were present in the urine and
bladder samples (P , 0.05) at day 3 of infection. The kidneys
were colonized equally by both strains.
Evaluation of additional CNF1-postive and CNF1-negative
isogenic pairs of UPEC strains early in the infection of C3H/
HeOuJ mice in the UTI model. To determine whether our
findings obtained with the CP9 and CP9cnf1 pair could be
reproduced with other such pairs, we did comparative analyses
of the numbers of C85 and C189 bacteria with those of their
respective isogenic mutants at days 1 and 2 postinoculation.
We found that the importance of CNF1 to the colonization
levels of C85 and C189 differed. At 1 day postinoculation,
C3H/HeOuJ mice infected with 1.9 3 107 C85 or C85cnf1
bacteria had equivalent numbers of CFU in the kidneys
whereas the numbers of wild-type bacteria in the urine and
bladders were slightly lower than those of mutant bacteria
(data not shown). In contrast, when mice that were inoculated
with 1.0 3 108 CFU of strains C189 and C189cnf1 were exam-
ined at 2 days postchallenge (day 1 was not tested), statistically
significantly higher numbers of wild-type bacteria were found
in the urine and bladders (Fig. 4). Colonization of the kidneys
showed a trend toward higher numbers of C189 than C189cnf1
bacteria, but this trend was not statistically significant.
Although significantly higher levels of C189 than C189cnf1
FIG. 1. Comparison of different CNF1-positive UPEC strains in
the C3H/HeOuJ mouse model of ascending UTI. Ten female C3H/
HeOuJ mice per bacterial strain were inoculated with 1.0 3 108 CFU
and sacrificed 3 days later. Urine, bladders, and kidneys were collected
and homogenized, and serial dilutions were plated for colony counts.
(A) Bacterial counts in urine. (B) Bacterial counts in bladders. (C)
Bacterial counts in kidneys. Each point represents one sample. The
height of the bar represents the mean for those samples. In all cases
except C189 in the bladder, the counts for J96 were significantly lower
than those of CP9, C85, and C189 (analysis of variance, P , 0.0001,
followed by Student’s t test, P , 0.05).
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bacteria were observed at 2 days postinoculation in the urine
and bladders of infected mice and experiments done over a
3-day period with strain CP9 and its isogenic mutant showed a
trend toward greater colonization of the urine and bladder by
the wild-type strain, there was significant variability from ex-
periment to experiment. We speculated that much of this vari-
ability was a consequence of the precision with which the
inoculum was introduced intravesically into the animal and/or
differences in the individual animal’s response to infection. To
control for experimental variation among animals, we next
tested CP9 against CP9cnf1 in a mixed-infection model.
Mixed-strain infections. The mixed-infection model allows
direct comparison of two strains in a single animal and elimi-
nates the variation between animals that is inherent in the
single-infection model system. Therefore, a Lac-negative de-
rivative of CP9 was generated by UV irradiation for use in
such an experiment. This CNF1-producing strain, designated
CP9lacZ, could be differentiated from Lac-positive CP9cnf1 on
MacConkey agar. To confirm that generation of the Lac2
phenotype did not alter the virulence of CP9lacZ, that strain
was tested against the parental strain in a mixed infection. The
two strains were mixed in a 1:1 ratio and used to inoculate
C3H/HeOuJ mice intravesically (Fig. 5A). Urine and kidney
samples from mice euthanatized 2 days postinoculation con-
tained equal numbers of each strain. Slightly higher numbers
of wild-type CP9 bacteria were found in the bladders, but the
difference in the numbers of each strain was not significant.
Based on these data, it was determined that CP9lacZ could
infect mice as well as CP9. CP9lacZ was then tested against
CP9cnf1 in the mixed-infection model. The strains were mixed
in equal numbers and used at an inoculum of 108 CFU per
strain, a dose similar to that previously shown to discriminate
well between CP9 and CP9cnf1 in single-dose experiments at 3
days postinfection (Fig. 3C). This mixture was used to infect
C3H/HeOuJ mice (Fig. 5B). Two days postinfection, CNF1-
positive CP9lacZ had grown to significantly higher numbers
than CP9cnf1 in the urine, bladders, and kidneys of the mice
tested (P , 0.05; Fig. 5B). Next, a time course study was done
with the same mixture of CP9lacZ and CP9cnf1 as in the
previous experiment. Mice were infected intravesically with the
mixture and sacrificed 6 h, 2 days, 4 days, 7 days, and 9 days
postinoculation (Fig. 6). In the urine, the numbers of CFU of
both strains increased between 6 h and 2 days. Between 2 and
9 days, the number of CFU of each strain decreased but the
decrease in the number of CP9cnf1 bacteria was more rapid than the
decrease in the number of CP9lacZ bacteria (Fig. 6A). In the blad-
der, the number of CFU of CP9lacZ bacteria was stable throughout
the experiment while the number of CP9cnf1 CFU decreased (Fig.
6B). CP9cnf1 and CP9lacZ numbers decreased in the kidneys during
the 9-day period, with the average number of CP9lacZ CFU decreas-
ing by 1.5 log units (Fig. 6C). In contrast, CP9cnf1 was nearly cleared
from the kidneys after 9 days. The average numbers of CFU of the
cnf1 isogenic mutant decreased by 5.8 log units (Fig. 6C), and in
100% (six of six) of the infected kidneys, bacteria were only detect-
able after enrichment culture. Results of the mixed-infection time
course study indicate that the wild-type strain consistently colonized
the mice at higher levels than did the cnf1 isogenic mutant strain. In
addition, there was more rapid clearing of the mutant strain from the
urinary tracts of the mice.
FIG. 2. Kinetics of UTI of C3H/HeOuJ mice with CP9 and the cnf1
isogenic mutant CP9cnf1. Thirty female C3H/HeOuJ mice were inoc-
ulated transurethrally with 1.9 3 107 CFU of either CP9 or CP9cnf1
bacteria and sacrificed 1, 3, and 5 days later. Urine, bladder, and
kidney samples were recovered, homogenized, and plated for colony
counts. Urine samples were not obtained from every mouse, and mice
that did not become infected were not included in the analysis. (A)
Bacterial counts 1 day after infection. (B) Bacterial counts 3 days after
infection. (C) Bacterial counts 5 days after infection. Each point rep-
resents one sample. The height of the bar represents the mean for
those samples. Symbols: ‚, CP9; Œ, CP9cnf1.
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Complementation of CP9cnf1 with a cloned cnf1
1 gene. The
results obtained with the mixed-infection model indicated
higher colonization of the urinary tract by the wild-type
strain. To confirm our assumption that the defect of CP9cnf1
was, in fact, a consequence of the absence of CNF1 expres-
sion, we attempted in vivo complementation studies. The
cnf1
1 gene was cloned from cosmid 2CO2 into pSX34lacZa,
a low-copy-number vector derived from pSC101. The result-
ing construct, designated pHLK140, was transformed into
CP9cnf1 and expressed CNF1 at a level that was five times
higher than wild-type expression in CP9. However, we found
that pHLK140 was not stable in vitro, either in the presence
or in the absence of antibiotic selection, perhaps due to the
toxicity of overexpressed CNF1. When tested in the mouse
model, the vector alone was stable in the absence of antibi-
otic selection. Similar to our findings with in vitro passage of
transformants harboring pHLK140, this plasmid was not
completely stable in vivo in the absence of selection. Loss of
the plasmid was detected in the urine and kidney samples
but not in the bladder samples. In mixed complementation
infection experiments with CP9lacZ(pSX34lacZa) (Lac neg-
ative, CNF1 positive, vector only) and CP9cnf1(pHLK140)
(Lac positive, CNF1 positive), there were no differences in
the numbers of bacterial CFU recovered from the bladders.
pHLK140 was retained by 83% of CP9cnf1 in the urine and
73% of CP9cnf1 in the kidneys, and half as many of these
bacteria were recovered from either site as were CNF1-
positive CP9lacZ(pSX34lacZa) bacteria. Thus, functional
complementation appears to have occurred in the bladders,
indicating some selective pressure for retention of the plas-
mid in the bladders, but not in the urine or kidneys, of the
mice. We cannot preclude the possibility that overexpres-
sion of CNF1 in the kidneys impaired the survival of the
mutant at that site. These results, taken together with the
FIG. 3. Comparison of CP9 and the cnf1 isogenic mutant CP9cnf1 at 1 to 3 days after inoculation of C3H/HeOuJ or BALB/c mice. (A) Twenty
female C3H/HeOuJ mice were inoculated with 1.9 3 107 CFU and sacrificed 1 day later. Organ samples were collected, homogenized, serially
diluted, and plated on LB agar. Symbols: ‚, CP9; Œ, CP9cnf1. (B) Fifteen female BALB/c mice were infected with 1.9 3 10
7 CFU and sacrificed
for colony counts 1 day later. Symbols: ‚, CP9; Œ, CP9cnf1. (C) Fifteen female C3H/HeOuJ mice were infected with 1.9 3 10
7 CFU and sacrificed
2 days later. Symbols: ‚, CP9; Œ, CP9cnf1. (D) Ten female C3H/HeOuJ mice were infected with 1 3 10
8 CFU and euthanatized 3 days later. Counts
of CP9 bacteria were significantly higher than those of CP9cnf1 in the urine and bladders (Student’s t test, P , 0.05). Symbols: ‚, CP9; Œ, CP9cnf1.
Each point represents one sample. The height of the bar represents the mean for those samples. Urine samples were not obtained from every
mouse, and mice that did not become infected were not included in the analysis.
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results of the single- and mixed-infection experiments, indi-
cate that production of CNF1 allows better infection of the
bladder by UPEC.
Histological analysis of bladder samples and light micro-
scopic examination of urine from infected mice. Single and
mixed infections, as well as complementation experiments,
showed that in the mouse model of UTI, CNF1 conferred an
advantage on CP9 in the bladder. Therefore, we focused our
histological evaluations on formalin-fixed bladder tissue from
mice infected with that strain or CP9cnf1. Microscopic exami-
nation of infected bladder sections stained with hematoxylin
and eosin revealed that both wild-type and mutant strains
elicited an acute inflammatory response from the host that
consisted of an influx of neutrophils and edema. The location
of the influx of neutrophils ranged from the epithelium only in
some bladders through the muscularis in others. The percent-
age of bladders infected with CP9 that exhibited moderate-to-
severe inflammation (Table 2) was higher than in the CP9cnf1-
infected bladders (100% versus 20%). These comparative data
from isogenic strains that differ only in CNF1 production sug-
gest that inflammation of the submucosa and muscularis may
be more severe in the bladders of animals infected with CNF1-
positive bacteria. In support of this premise, bacteria were
visible (by Brown-Brenn staining) within the areas of inflam-
mation (data not shown).
Killing of bacteria by neutrophils. The finding of increased
inflammation within the bladder tissue of wild-type-infected
mice compared to mutant-infected animals prompted us to
examine the interaction of neutrophils with the bacteria. We
examined the ability of freshly isolated human neutrophils to
kill CP9 and CP9cnf1 after incubation of the bacteria and
neutrophils together for 15 and 45 min. Despite day-to-day
variation in neutrophil viability and bactericidal activity, iso-
lated neutrophils were less effective in killing wild-type CP9
than in killing CP9cnf1 (data not shown). In seven of eight
samples, the viability of CP9 after 15 or 45 min of exposure to
neutrophils was significantly greater than that of CP9cnf1 (P ,
0.05). Lysates prepared from the CP9-neutrophil mixture after
incubation expressed CNF1, as demonstrated by the multinucle-
ation of HEp-2 cells. This activity was not present in the
CP9cnf1-neutrophil incubation mixture. These data indicated
that human neutrophils kill CNF1-negative UPEC more effec-
tively than they kill isogenic CNF1-positive UPEC.
DISCUSSION
In this investigation, we sought to test the hypothesis that
CNF1 contributes to the virulence of UPEC through the use of
a mouse model of ascending UTI. Prior to this report, the
evidence in favor of such a proposal was primarily based on
FIG. 4. Single-strain infection comparing C189 with C189cnf1 2
days after inoculation. Seven female C3H/HeOuJ mice were inocu-
lated with 1.0 3 108 CFU and sacrificed 2 days after challenge. Points
represent individual samples, and the height of each bar represents the
geometric mean of those samples. Counts of C189 were significantly
higher than those of C189cnf1 in the urine and bladders (Student’s t
test, P , 0.05). Symbols: ‚, C189, Œ, C189 cnf1.
FIG. 5. Mixed infections of C3H/HeOuJ mice. Two strains were
mixed in equal numbers and inoculated into female mice. Mice re-
ceived 2.0 3 108 CFU and were sacrificed 2 days after infection. (A)
Mixed infections comparing CP9 (CNF11 Lac1) with CP9lacZ
(CNF11 Lac2). Eleven female C3H/HeOuJ mice were inoculated.
Symbols: ‚, CP9; Œ, CP9lacZ. (B) Mixed infections comparing
CP9lacZ with CP9cnf1. Twenty female C3H/HeOuJ mice were inocu-
lated. Counts of CP9lacZ were significantly higher than those of
CP9cnf1 in the urine, bladders, and kidneys (Student’s t test, P , 0.05).
Symbols: ‚, CP9lacZ, Œ, CP9cnf1. Points represent bacterial numbers
in individual samples, and bars represent the means of those samples.
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epidemiological findings (3, 6, 35, 45) and, more indirectly, the
cytopathic effects of CNF1 on a human bladder epithelial cell
line, 5637 (34). The evidence against such a theory was recently
presented by Johnson and colleagues (26). Those investigators
used the same general approach that we employed in our
investigation: a comparison of the net growth and histological
damage induced by a CNF1-positive UPEC strain to those of
its isogenic cnf1 mutant in a mouse model of ascending UTI.
Although we do not dispute the conclusions of those research-
ers that CNF1 did not contribute to the virulence of the UPEC
strain that they tested, our results, for the reasons described
below, led us to the opposite conclusion. Indeed, we generated
four lines of evidence to support our original tenet. First, in
single-challenge inoculation experiments, we showed that up to
3 days after single-strain intravesical challenge, two of the
three CNF1-producing strains tested achieved greater num-
bers in the urine and bladders of mice than did their respective
cnf1 isogenic mutants. On days 1, 2, and 3 after challenge, the
average numbers of CFU of CP9 were higher than the average
numbers of CFU of CP9cnf1 in the urine or bladders. Strain
C85 was only tested at day 1, and it was present in slightly lower
numbers in the urine and bladders than its cnf1 isogenic mutant
at that point of infection. C189 and its isogenic mutant were
tested only on day 2 of infection, and at that time, the wild-type
strain was present in higher numbers in the urine and bladders
than C189cnf1. Second, in mixed-inoculation studies, CP9 con-
sistently outgrew CP9cnf1 in the urine and tissues of the uri-
nary tract. Third, CNF1-positive strains CP9 and C85 induced
a greater degree of inflammation and appeared to traverse
deeper into the bladder tissue at day 1 of infection than did
CP9cnf1 and C85cnf1, respectively, even though the latter
strain was present at slightly higher numbers than its wild-type
parent. Fourth, CP9 survived better in the presence of human
neutrophils than did CP9cnf1.
That the conclusions of this study and the report of Johnson
et al. (13, 26) are contradictory may be explained, in part, on
the basis of differences in certain experimental variables used
by the two groups. The parameters that are known to alter the
severity and time course of single-strain challenge studies in
the mouse UTI model include the following. First, the type of
human isolate influences the infection, i.e., strains from a pa-
tient with cystitis or pyelonephritis (reference 27 and Fig. 1 of
this study). Indeed, Johnson and colleagues previously re-
ported that cystitis isolates colonize the mouse bladder and
urine better than do pyelonephritis isolates whereas pyelone-
phritis isolates colonize the kidneys at higher levels. The strain
used by Johnson et al. for their analysis of the contribution of
CNF1 to the urovirulence of E. coli in the mouse model was
F11, an isolate from the urine of a patient with symptoms of
cystitis (26). In our experiments, we primarily examined CP9, a
strain isolated from the blood of a patient (41). We also tested
C85 and C189, both of which are cystitis isolates. Second, the
strain of mouse used in the model may also affect the pattern
FIG. 6. CNF1 contributes to bacterial survival in a mixed infection.
Time courses of mixed infections with CP9lacZ and CP9cnf1 are
shown. The bacterial strains were mixed in equal numbers, and C3H/
HeOuJ mice received 2.0 3 108 CFU. Mice were sacrificed 6 h, 2 days,
4 days, 7 days, and 9 days after infection, and colony counts were
performed on collected samples. (A) Mean bacterial numbers in the
urine of infected mice. (B) Mean bacterial numbers in the bladders of
infected mice. (C) Mean bacterial numbers in the kidneys of infected
mice. ——, CP9lacZ; – – –, CP9cnf1. Each point represents the mean
number of CFU per sample for three mice.
TABLE 2. Severity of neutrophil influx in mouse bladders 1 day
after infection with CNF1-positive CP9 or its cnf1 isogenic mutant
Straina No. ofCFU/gb
Avg no. of
neutrophils
(range)c
Severity of
inflammationd
CP9 (6) 104–107 95 (39–181) 100
CP9 cnf1 (5) 10
5–107 39 (7–129) 20
a Numbers in parentheses are the numbers of mice tested.
b Range of bacterial counts present in the bladders examined.
c Neutrophils were counted within the tissue in the area of greatest inflam-
mation, and PMN in blood vessels were excluded (magnification, 3600). Slides
were coded and examined in a blinded fashion by a pathologist. All slides from
CP9-infected animals were reported to contain many more areas of inflammation
than the slides from animals infected with the CNF1-negative mutant. Inflam-
mation was scored as described in Materials and Methods.
d Percentage of animals with moderate to severe inflammation.
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of infection, as demonstrated by Hopkins et al. (22). Those
investigators examined the time course and host response of
various mouse strains to a single E. coli strain and concluded
that mice of various strains differ in their initial susceptibility to
infection and in the ability to resolve an infection. In our
studies, infection of BALB/c mice with CP9 and CP9cnf1 re-
sulted in higher numbers of the mutant strain in the urine and
kidneys of the mice (but not the bladder) at 1 day of infection.
Conversely, when C3H/HeOuJ mice were infected with the
same dose and the same strains, there were higher numbers of
the wild-type strain than the mutant in the urine and bladders
of the mice on that first day of infection. In addition, the
overall numbers of bacteria in the urine and tissues of C3H/
HeOuJ mice were higher than the numbers in the comparable
specimens from BALB/c mice. These differences could indi-
cate that for the BALB/c infections, the time of sampling was
not optimal for observation of an effect of CNF1 on the infec-
tion process. In contrast, the data could also indicate that
CNF1 does not play a role in the infection of BALB/c mice.
Since Johnson et al. used CBA/J/Hsd mice (26), perhaps the
absence of a demonstrable effect of CNF1 on the urovirulence
of F11 could reflect their choice of mouse strains for these
experiments. Third, the time in infection at which the compar-
ison between a CNF1-positive and a CNF1-negative strain was
made had an impact in our studies of mice that were inocu-
lated with single bacterial strains (earlier was generally better
at a comparable dose). We focused our single-strain infection
experiments on days 1 to 3; Johnson et al. focused most of their
experiments on a 7-day infection period. Fourth, the challenge
dose might have an impact on the outcome of a differential
analysis between the wild type and an isogenic cnf1 mutant. We
generally used an inoculum of 2 3 107 CFU per mouse in
single-strain studies, while Johnson and colleagues used a dose
of 2 3 109 CFU. The higher dose might obscure the type of
trends that we observed between CNF1-postive and CNF1-
negative isogenic mutants in single-strain inoculation experi-
ments. Finally, the spectrum of additional virulence determi-
nants expressed by a particular UPEC strain (e.g., hemolysin,
cytolethal distending toxin) might alter or mask the influence
that CNF1 has on the pathogenesis of infection. In fact, in our
study, the only strain pair in which a statistically significant
difference in colony counts (rather than a trend) was observed
between the wild-type and mutant strains in single-strain in-
fection studies was with the hemolysin-negative isolate C189.
Taken together, the general trends of our single-strain chal-
lenge studies with C3H/HeOuJ mice suggested that CNF1
contributed to UTI early in the infection process in the mouse
model in two of the three strains tested. However, the variation
in bacterial numbers in each animal test group made it difficult
to draw definitive conclusions supported by statistically signif-
icant differences in the geometric mean numbers of CFU. This
wide range of counts within experimental groups has been
previously demonstrated (26, 37) and may reflect differences
between individual animals’ responses to infection. Some in-
dividual animals may clear the initial infection faster than
others because of their immune system efficiency or the speed
with which the animals urinate after infection. Regardless of
the reason for the variability, when such variation among an-
imals was minimal or experimentally controlled for by utilizing
mixed infections (see below), there were statistically significant
differences between the numbers of CFU of strains CP9 and
CP9cnf1 recovered from the urine.
A mixed-infection model was utilized to control for the vari-
ation in severity of infection from animal to animal. To our
knowledge, this is the first published study comparing a CNF1-
positive strain to an isogenic CNF1-negative mutant in a
mixed-infection model. We generated a Lac-negative mutant
of strain CP9 (CP9lacZ) to differentiate the parent from the
isogenic cnf1 mutant. When equal numbers of CP9lacZ and
CP9cnf1 bacteria were inoculated into mice, CP9lacZ was re-
covered in significantly higher numbers from the urinary tract
than CP9cnf1. The capacity of CP9lacZ to outgrow CP9cnf1 in
the urinary tract was not due to a difference between the
growth rates of the bacteria, as demonstrated in vitro. Rather,
CNF1 appeared to confer an advantage on the bacterium in
the urinary tract. In fact, time course studies of mixed infec-
tions showed that the CNF1-positive strain was able to persist
in the bladder and kidneys whereas CP9cnf1 was cleared more
rapidly from the urinary tract. In a previous report, Miller and
Creaghe described mixed-infection studies with two unrelated
E. coli strains isolated from a patient with pyelonephritis (33).
When they inoculated a mixed culture directly into the kidney,
they found stable cocolonization of the kidney, but when in-
oculation was by a retrograde infection, a serogroup O8 strain
was found to infect the kidneys to the exclusion of a serogroup
O75 strain. The investigators concluded that bacterial interfer-
ence played some part in infection of the kidney by a single
strain. The influence of virulence factors was not discussed in
that report, but another explanation for these results may be
that the O8 strain possessed virulence determinants that gave
that strain an advantage over the other strain. Our experimen-
tal design differs from that of Miller and Creaghe in that we
used isogenic strains isolated from blood that varied only in
CNF1 production and lactose utilization. We concluded that
the capacity of CP9lacZ to colonize the urinary tract in higher
numbers than CP9cnf1 is due to the presence of CNF1.
We examined the basis for the apparent advantage that
production of CNF1 conferred on UPEC strains in this model.
Histological analysis of bladder samples taken from mice 1 day
after infection indicated that CNF1-positive bacteria caused
severe inflammation more often than the isogenic mutants
(Table 2). Functional complementation of the cnf1 mutant also
was evident in the bladder, a result consistent with a role for
CNF1 in UPEC pathogenesis at that site. One possible benefit
of CNF1 production by bacteria in bladder tissues is that the
toxin induces epithelial cells to take up the bacteria and pro-
mote their transcytosis across the mucosal barrier. In fact,
Falzano et al. reported that CNF1 induced phagocyte-like ac-
tivity in human epithelial cells, allowing the uptake of nonin-
vasive bacteria (9). Alternatively, cell death caused by CNF1
(34) or tissue damage due to a more intense inflammatory
response to CNF1-positive strains may allow the infecting
strain to gain access to deeper tissues. Infiltration of PMN was
found more often in the mucosa and submucosa of bladders
infected with CNF1-positive strains. Abnormal multinucle-
ation was not evident in any of the bladder sections examined,
a finding consistent with a recent report on the differences in
the effects of CNF1 on human bladder 5637 cells (cytotoxicity)
and HEp-2 cells (multinucleation) (34).
That CNF1 production may increase the inflammatory re-
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sponse of the host is suggested by our observations and the
work of others. Specifically, Elliott et al. reported that CNF1
evokes edema and necrosis and is associated with inflamma-
tion in the intestines of rabbits in a diarrhea model of infection
(7). Additionally, Fournout et al. found that germfree piglets
infected orally with a CNF1-positive E. coli strain developed
pulmonary inflammation more frequently than those infected
with an isogenic CNF1-negative mutant (13). In that study,
CNF1-positive and CNF1-negative bacteria were both dissem-
inated in the lungs of the infected pigs. Hofman et al. recently
reported that treatment of isolated PMN with purified CNF1
for 16 h, followed by stimulation with zymosan, resulted in an
increase in superoxide generation and adherence of PMN to
T84 cells; however, the phagocytic function of CNF1-treated
PMN was decreased (19). Our observation that human neu-
trophils are less effective at killing CNF1-positive bacteria than
CNF1-negative bacteria may result from decreased phagocy-
tosis of the bacteria by the neutrophils.
If CNF1 gives bacteria an advantage in persistence in the
lower urinary tract, how does that happen in the face of the
host responses to bacterial entry into the bladder? The defen-
sive responses of the host include the washout flow of urine,
shedding of the uroepithelium, and production of an acute
inflammatory response, with the resultant production of host
cytokines, such as interleukins 6 and 8, that increase the influx
of polymorphonuclear lymphocytes into the area (1, 2, 17). Our
results show that CNF1 production protects UPEC from kill-
ing by neutrophils. That result should be viewed in the context
of the fact that CNF1-producing bacteria have been reported
to evoke greater granulocyte colony-stimulating factor levels in
patients than E. coli strains that do not produce CNF1 (25).
Granulocyte colony-stimulating factor plays a role in maintain-
ing the normal blood neutrophil count and determining the
neutrophilic response to infection in the human host. Thus, in
spite of an apparent capacity of CNF1-positive bacteria to
recruit neutrophils to the site of infection, the toxin acts to
protect the bacteria from neutrophilic attack.
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